Roche's Tecentriq Positive But Not Perfect In IMpower130 First-line Lung Cancer Study
Combination with Abraxane demonstrates an overall survival benefit on top of progression-free survival, but Merck's competing Keytruda has set a high benchmark for first-line metastatic lung cancer.
You may also be interested in...
EU approval of Tecentriq and Avastin together with chemo for the first-line treatment of metastatic non-squamous NSCLC is a positive advance for Roche, but analysts say the combo has a long way to go still to catch up with Merck & Co’s Keytruda combination.
The latest drug development news and highlights from our US FDA Performance Tracker.
While the failure of AstraZeneca's Imfinzi in the MYSTIC trial for stage IV lung cancer is a blow, it is not going to have much of an effect on the potential for the company which has carved out a sizeable niche for the drug in stage III NSCLC.